Amyl nitrite, which targets the NPR1 gene, emerges as a potential therapeutic option for NSIAD, confirming the consistency of TXGNN’s explanations with medical evidence. Here, NPR1 is linked to nephrogenic syndrome of inappropriate antidiuresis.